158 related articles for article (PubMed ID: 16985050)
1. Cyclin D3 is down-regulated by rapamycin in HER-2-overexpressing breast cancer cells.
García-Morales P; Hernando E; Carrasco-García E; Menéndez-Gutierrez MP; Saceda M; Martínez-Lacaci I
Mol Cancer Ther; 2006 Sep; 5(9):2172-81. PubMed ID: 16985050
[TBL] [Abstract][Full Text] [Related]
2. Roles of human epidermal growth factor receptor 2, c-jun NH2-terminal kinase, phosphoinositide 3-kinase, and p70 S6 kinase pathways in regulation of cyclin G2 expression in human breast cancer cells.
Le XF; Arachchige-Don AS; Mao W; Horne MC; Bast RC
Mol Cancer Ther; 2007 Nov; 6(11):2843-57. PubMed ID: 18025271
[TBL] [Abstract][Full Text] [Related]
3. Role of glycogen synthase kinase 3beta in rapamycin-mediated cell cycle regulation and chemosensitivity.
Dong J; Peng J; Zhang H; Mondesire WH; Jian W; Mills GB; Hung MC; Meric-Bernstam F
Cancer Res; 2005 Mar; 65(5):1961-72. PubMed ID: 15753396
[TBL] [Abstract][Full Text] [Related]
4. Rapamycin inhibits human renal epithelial cell proliferation: effect on cyclin D3 mRNA expression and stability.
Pallet N; Thervet E; Le Corre D; Knebelmann B; Nusbaum P; Tomkiewicz C; Meria P; Flinois JP; Beaune P; Legendre C; Anglicheau D
Kidney Int; 2005 Jun; 67(6):2422-33. PubMed ID: 15882288
[TBL] [Abstract][Full Text] [Related]
5. Determinants of rapamycin sensitivity in breast cancer cells.
Noh WC; Mondesire WH; Peng J; Jian W; Zhang H; Dong J; Mills GB; Hung MC; Meric-Bernstam F
Clin Cancer Res; 2004 Feb; 10(3):1013-23. PubMed ID: 14871980
[TBL] [Abstract][Full Text] [Related]
6. Rapamycin together with herceptin significantly increased anti-tumor efficacy compared to either alone in ErbB2 over expressing breast cancer cells.
Wang LH; Chan JL; Li W
Int J Cancer; 2007 Jul; 121(1):157-64. PubMed ID: 17304506
[TBL] [Abstract][Full Text] [Related]
7. Plumbagin induces G2-M arrest and autophagy by inhibiting the AKT/mammalian target of rapamycin pathway in breast cancer cells.
Kuo PL; Hsu YL; Cho CY
Mol Cancer Ther; 2006 Dec; 5(12):3209-21. PubMed ID: 17172425
[TBL] [Abstract][Full Text] [Related]
8. Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2.
Basso AD; Solit DB; Munster PN; Rosen N
Oncogene; 2002 Feb; 21(8):1159-66. PubMed ID: 11850835
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of Hsp90 function by ansamycins causes retinoblastoma gene product-dependent G1 arrest.
Srethapakdi M; Liu F; Tavorath R; Rosen N
Cancer Res; 2000 Jul; 60(14):3940-6. PubMed ID: 10919672
[TBL] [Abstract][Full Text] [Related]
10. The molecular target of rapamycin (mTOR) as a therapeutic target against cancer.
Mita MM; Mita A; Rowinsky EK
Cancer Biol Ther; 2003; 2(4 Suppl 1):S169-77. PubMed ID: 14508096
[TBL] [Abstract][Full Text] [Related]
11. Mammalian target of rapamycin: a new molecular target for breast cancer.
Mita MM; Mita A; Rowinsky EK
Clin Breast Cancer; 2003 Jun; 4(2):126-37. PubMed ID: 12864941
[TBL] [Abstract][Full Text] [Related]
12. Androgens induce prostate cancer cell proliferation through mammalian target of rapamycin activation and post-transcriptional increases in cyclin D proteins.
Xu Y; Chen SY; Ross KN; Balk SP
Cancer Res; 2006 Aug; 66(15):7783-92. PubMed ID: 16885382
[TBL] [Abstract][Full Text] [Related]
13. Stem cell factor/c-kit up-regulates cyclin D3 and promotes cell cycle progression via the phosphoinositide 3-kinase/p70 S6 kinase pathway in spermatogonia.
Feng LX; Ravindranath N; Dym M
J Biol Chem; 2000 Aug; 275(33):25572-6. PubMed ID: 10849422
[TBL] [Abstract][Full Text] [Related]
14. Rapamycin-induced G1 arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A, and survivin.
Decker T; Hipp S; Ringshausen I; Bogner C; Oelsner M; Schneller F; Peschel C
Blood; 2003 Jan; 101(1):278-85. PubMed ID: 12393642
[TBL] [Abstract][Full Text] [Related]
15. Rapamycin inhibits hTERT telomerase mRNA expression, independent of cell cycle arrest.
Bae-Jump VL; Zhou C; Gehrig PA; Whang YE; Boggess JF
Gynecol Oncol; 2006 Mar; 100(3):487-94. PubMed ID: 16249016
[TBL] [Abstract][Full Text] [Related]
16. Rapamycin disrupts cyclin/cyclin-dependent kinase/p21/proliferating cell nuclear antigen complexes and cyclin D1 reverses rapamycin action by stabilizing these complexes.
Law M; Forrester E; Chytil A; Corsino P; Green G; Davis B; Rowe T; Law B
Cancer Res; 2006 Jan; 66(2):1070-80. PubMed ID: 16424043
[TBL] [Abstract][Full Text] [Related]
17. Adhesion-regulated G1 cell cycle arrest in epithelial cells requires the downregulation of c-Myc.
Benaud CM; Dickson RB
Oncogene; 2001 Jul; 20(33):4554-67. PubMed ID: 11494151
[TBL] [Abstract][Full Text] [Related]
18. Anti-HER2 antibody trastuzumab inhibits CDK2-mediated NPAT and histone H4 expression via the PI3K pathway.
Le XF; Bedrosian I; Mao W; Murray M; Lu Z; Keyomarsi K; Lee MH; Zhao J; Bast RC
Cell Cycle; 2006 Aug; 5(15):1654-61. PubMed ID: 16861913
[TBL] [Abstract][Full Text] [Related]
19. Mechanism of action of the immunosuppressant rapamycin.
Dumont FJ; Su Q
Life Sci; 1996; 58(5):373-95. PubMed ID: 8594303
[TBL] [Abstract][Full Text] [Related]
20. Regulation of D-cyclin translation inhibition in myeloma cells treated with mammalian target of rapamycin inhibitors: rationale for combined treatment with extracellular signal-regulated kinase inhibitors and rapamycin.
Frost P; Shi Y; Hoang B; Gera J; Lichtenstein A
Mol Cancer Ther; 2009 Jan; 8(1):83-93. PubMed ID: 19139116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
